Solid-State Nuclear Magnetic Resonance in Pharmaceutical Compounds

被引:22
|
作者
Alberto Monti, Gustavo [1 ,2 ]
Karina Chattah, Ana [1 ,2 ]
Garro Linck, Yamila [2 ]
机构
[1] FaMAF Univ Nacl Cordoba, Cordoba, Argentina
[2] IFEG CONICET, Cordoba, Argentina
来源
ANNUAL REPORTS ON NMR SPECTROSCOPY, VOL 83 | 2014年 / 83卷
关键词
SSNMR; Pharmaceutical compounds; Characterization; NMR crystallography; Polymorphism; Complexes; C-13 CPMAS NMR; QUANTITATIVE CROSS-POLARIZATION; CRYSTAL-STRUCTURE; SUPRAMOLECULAR COMPLEXES; MAS NMR; STRUCTURAL-CHARACTERIZATION; DISSOLUTION PROPERTIES; FUROSEMIDE POLYMORPHS; ROTARY RESONANCE; CRYSTALLOGRAPHY;
D O I
10.1016/B978-0-12-800183-7.00004-6
中图分类号
O433 [光谱学];
学科分类号
0703 ; 070302 ;
摘要
The solid-state characterization of novel pharmaceutical compounds remains an important issue. Solid-state NMR is one of the techniques of choice to gain information when other techniques are not available. Knowledge of the molecular structure in the solid state can lead to better design and control the behaviour of the drug as it affects important properties such as solubility in aqueous medium. Many different NMR experiments can be performed to obtain either structural or dynamic information on very broad space and time ranges, respectively. Contrary to others techniques, not only crystalline material but also amorphous materials can be studied by SSNMR. These and other aspects make SSNMR a very powerful technique to obtain relevant information on solids pharmaceutical forms. We will discuss the SSNMR most common experiments used to investigate pharmaceutical compounds, including one-and two-dimensional experiments and relaxation time measurements. Additionally, we will mention some aspects of first principle calculation. Also we highlight the importance of NMR as a multinuclear technique. We will focus on SSNMR applied for characterization of new developed active pharmaceutical compounds and formulated drugs. We will pay attention to some particular topics as polymorphism, complexes with cyclodextrin and an emerging issue in pharmaceutical industry as it is the development of cocrystals. NMR crystallography is also discussed.
引用
收藏
页码:221 / 269
页数:49
相关论文
共 50 条
  • [1] Solid-state of pharmaceutical compounds
    D. Giron
    M. Mutz
    S. Garnier
    Journal of Thermal Analysis and Calorimetry, 2004, 77 (2) : 709 - 747
  • [2] Floquet theory in solid-state nuclear magnetic resonance
    Leskes, Michal
    Madhu, P. K.
    Vega, Shimon
    PROGRESS IN NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, 2010, 57 (04) : 345 - 380
  • [3] Solid-state nuclear magnetic resonance spectroscopy of cements
    Walkley, B.
    Provis, J. L.
    MATERIALS TODAY ADVANCES, 2019, 1
  • [4] The role of solid-state nuclear magnetic resonance in crystal engineering
    Xu, Yijue
    Southern, Scott A.
    Szell, Patrick M. J.
    Bryce, David L.
    CRYSTENGCOMM, 2016, 18 (28): : 5236 - 5252
  • [5] Recent Advances in Solid-State Nuclear Magnetic Resonance Spectroscopy
    Ashbrook, Sharon E.
    Griffin, John M.
    Johnston, Karen E.
    ANNUAL REVIEW OF ANALYTICAL CHEMISTRY, VOL 11, 2018, 11 : 485 - 508
  • [6] Heteronuclear Spin Decoupling in Solid-State Nuclear Magnetic Resonance: Overview and Outlook
    Madhu, P. K.
    ISRAEL JOURNAL OF CHEMISTRY, 2014, 54 (1-2) : 25 - 38
  • [7] Structure and properties of materials by solid-state nuclear magnetic resonance
    Bryce, David Lawson
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2017, 73 : C9 - C9
  • [8] Sodium-23 solid-state nuclear magnetic resonance of commercial sodium naproxen and its solvates
    Burgess, Kevin M. N.
    Perras, Frederic A.
    Lebrun, Aurore
    Messner-Henning, Elisabeth
    Korobkov, Ilia
    Bryce, David L.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (08) : 2930 - 2940
  • [9] Characterization of Pharmaceutical Compounds by Solid-state NMR
    Vogt, Frederick G.
    EMAGRES, 2015, 4 (02): : 255 - 268
  • [10] Solid-state nuclear magnetic resonance in the structural study of polyglutamine aggregation
    van der Wel, Patrick C. A.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2024, 52 (02) : 719 - 731